Active substance
Sulfadiazine
- US FDA 8
- UK MHRA 1
- US price lines 1
- NHS prices 1
- WHO EML 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| SULFADIAZINE | 500MG | tablet · oral | EPIC PHARMA LLC | Prescription | 29 Jul 1994 |
| SULFADIAZINE | 500MG | tablet · oral | LEDERLE | Discontinued | 11 Aug 1941 |
| SULFADIAZINE SODIUM | 250MG/ML | injectable · injection | LEDERLE | Discontinued | 11 Aug 1941 |
| SULFADIAZINE | 500MG | tablet · oral | LILLY | Discontinued | 26 Aug 1941 |
| SULFADIAZINE | 500MG | tablet · oral | CHARTWELL MOLECULAR | Discontinued | 5 Jul 1978 |
| SULFADIAZINE | 500MG | tablet · oral | IMPAX LABS | Discontinued | |
| SULFADIAZINE | 500MG | tablet · oral | EVERYLIFE | Discontinued | |
| SULFADIAZINE | 300MG | tablet · oral | ABBVIE | Discontinued |
UK MHRA United Kingdom — marketing authorisations
| Product | Authorisation | Holder | Legal status |
|---|---|---|---|
| SULFADIAZINE 500MG TABLETS BP | PL 29831/0191 | WOCKHARDT UK LIMITED | POM |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | SULFADIAZINE 500 MG TABLET | $15.06467 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Sulfadiazine 500mg tablets | £395.42 | 56 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.5.4. Antipneumocystosis and antitoxoplasmosis medicines · core
Toxoplasmosis
Oral > Solid: 500 mg
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.